

REMARKS

With this amendment, claims 1, 3, 4, 9-14, 16, 20, 22, 26, 28, 29, 34-37, 41, 52-57, and 71 have been amended to clarify that which Applicants regard as their invention. Claims 2, 27, 51 and 62-70 have been cancelled. Claims 1, 9-13, 16, 20, 26, 34-37, 41, 52-57, and 71 have been amended to delete the term "organism" in favor of "species". Claims 1, 26, 52, and 71 have been amended to recite a phenotypic data structure that **comprises** a difference in a phenotype between different strains of a species. Claims 1, 26, and 52 have been further amended to recite that an amount of a genome that is included in a locus in a plurality of loci is predetermined. Claims 1, 12, 14, 16, 26, 52 and 71 have been amended to recite a genotypic data structure that **comprises** a variation (or a plurality of variations) of at least one component of a locus between different strains of a species. Claims 3, 4, 28 and 29 have been amended to correct for antecedent basis as a result of the cancellation of claims 2 and 27. Claim 54 has also been amended to correct for antecedent basis. Claims 9, 11, 34, and 53 have been amended to recite that each element in a phenotypic data structure corresponds to a difference in a phenotype. New claims 72-77 have been added to more particularly recite certain aspects of the present invention. No new matter has been added by virtue of these claim amendments and new claims.

Upon entry of the present amendments, claims 1, 3-26, 28-50, 52-61, and 71-77 will be pending in the above-identified application.

INFORMATION DISCLOSURE STATEMENTS

Applicants have submitted three information disclosure statements in the above-identified case. With this response, a fourth information disclosure statement has been submitted. The first information disclosure statement, containing references AA through AV, was submitted at the time of filing on December 11, 2001. The second information disclosure statement, containing references AW through BJ was submitted on August 7, 2002. The third information disclosure statement, containing references BK through BM, was submitted on September 27, 2002.

In the October 21, 2003 Office Action, the examiner enclosed signed off copies of the list of references cited in the second and third information disclosure statements (references AW through BM) but not the list of references cited in the first information disclosure

statement (references AA through AV). Attorneys for Applicants called Examiner C. Dune Ly on November 25, 2003 to notify the Examiner of this omission. In this telephone conference, Examiner Ly agreed to consider references AA through AV in the next office action. Applicants note that reference AA is identical to reference BJ and therefore respectfully request that reference AA be stricken so that it is not printed twice on the cover of any patent that may issue in the above identified case.

THE PROVISIONAL STATUTORY 35 U.S.C. § 101 DOUBLE PATENTING REJECTION SHOULD BE WITHDRAWN

The PTO has provisionally rejected claims 1 and 9 on statutory 35 U.S.C. § 101 double patenting grounds for allegedly claiming the same invention as that of claims 1 and 2 of copending Application No. 09/737,918.

Section 804 II. A. of the Manual of Patent Examining Procedure ("M.P.E.P.", Eight Edition, August 2001, February 2003 revision) states that statutory double patenting does not exist if there is an embodiment of the invention that falls within the scope of a claim in one application but does not fall within the scope of the corresponding claim in the other application. For example, the invention defined by a claim reciting a compound having a "halogen" substituent is not identical to or substantively the same as a claim reciting the same compound except having a "chlorine" substituent in place of the halogen because "halogen" is broader than "chlorine." Thus, double patenting in this example is without basis according to section 804 II. A. of the M.P.E.P.

Applicants have revised claim 1 of the above-identified application to include the phrase "and wherein an amount of said genome that is included in each locus in said plurality of loci is predetermined." The feature of using a predetermined size for each locus is discussed on page 15, line 19, through page 16, line 4, of the specification. This feature is not disclosed in copending Application No. 09/737,918. Accordingly, Applicants respectfully request that the statutory double patenting rejection be withdrawn.

THE PROVISIONAL NON-STATUTORY 35 U.S.C. § 101 DOUBLE PATENTING REJECTION SHOULD BE WITHDRAWN

The PTO has provisionally rejected claims 1, 9-13, 16, 17, 24-26, 34-38, 41, 42, and 48-61 on 35 U.S.C. § 101 non-statutory double patenting grounds for allegedly claiming the same invention as that of claims 1-32 of copending Application No. 09/737,918. With

respect to claim 51, the provisional rejection is moot because Applicants have cancelled the claim. Although Applicants disagree with the PTO's reasoning, in order to expedite prosecution, Applicants have authorized the enclosed terminal disclaimer. Therefore, Applicants respectfully request that the non-statutory double patenting rejection be withdrawn.

THE 35 U.S.C. § 102 REJECTION SHOULD BE WITHDRAWN

The PTO has rejected claims 1-10, 12, 13, and 18 under 35 U.S.C. § 102(b) as allegedly being anticipated by Luo and Kearsy, 1992, "Interval mapping of quantitative trait loci in an F₂ population," *Heredity* 69, pp. 236-242 (hereinafter "Luo"). With respect to claim 2, the rejection is moot because the claim has been cancelled. With respect to claims 1, 3-10, 12, 13, and 18, Applicants respectfully traverse the rejection.

The standard for anticipation under 35 U.S.C. §102 is strict identity. Anticipation under §102 can only be established by a prior art reference that teaches each and every element of the claimed invention. *Structural Rubber Products Co. v. Park Rubber Co.* 223 USPQ 1264 (1984). Applicants respectfully submit that Luo fails to recite each and every limitation of pending claims 1, 3-10, 12, 13, and 18.

Luo is directed to a method of mapping and characterizing quantitative trait loci using F₂ data derived from inbred line crosses as well as marker information. In Luo, two inbred lines, P₁ and P₂, are crossed in order to create linkage disequilibrium between loci that differ in the two inbred lines. This linkage disequilibrium in turn creates associations between marker loci and linked segregating QTLs. An overview of the techniques used by Luo is found in Chapter 15 of Lynch and Walsh, *Genetics and Analysis of Quantitative Traits*, Sinauer Associates, Inc., Sunderland, Massachusetts, 1998 (reference BN of the attached supplemental information disclosure statement) as well as Doerge, 2003, *Nature Reviews Genetics* 3, pp. 43-52 (reference BO of the attached supplemental information disclosure statement). Central to these techniques is the modeling of segregated markers and QTL in a single population.

In the October 21, 2003 office action, the PTO equates the alleles respectively found in the two inbred lines P₁ and P₂ of Luo to the phenotypic data structure recited in claim 1. Further, the PTO equates the marker linkage map of Luo (in which a genome is separated into a series of chromosomal segments each of which is flanked by two marker loci) to the

genotypic data structure of claim 1 as amended. As will be discussed below, the claimed phenotypic data structure and the claimed genotypic data structure have no such counterpart in Luo.

Luo does not disclose the claimed phenotypic data structure. Applicants have amended claim 1 to recite a phenotypic data structure that comprises a difference in a phenotype between different strains of a species.

Page 14 of the specification provides the following example of the construction of a phenotypic data structure using five mouse strains. Consider the phenotypic data for lifespan:

Strains	Lifespan (days)
A/J	777
AKR/J	282
C3H/HeJ	510
C57BL/6J	895
DBA/2J	568

A phenotypic distance matrix that tracks the lifespan for these five species members has the form:

P	A/J	AKR/J	C3H/HeJ	C57BL/6J	DBA/2J
A/J	0	495	267	118	209
AKR/J	495	0	228	613	286
C3H/HeJ	267	228	0	385	58
C57BL/6J	118	613	385	0	327
DBA/2J	209	286	58	327	0

The phenotypic data structure is the non-redundant, non-diagonal elements of this matrix (P= 495, 267, 118, 209, 228, 613, 286, 385, 58, 327). As such, the phenotypic data structure comprises a difference in a phenotype between different strains of the species as recited in amended claim 1. For example, the phenotypic data structure includes the value 495, which

represents the difference in days between the lifespan of the AKR/J mouse strain and the A/J mouse strain.

Luo does not have a data structure that represents the difference in a phenotype between different strains of a species because Luo simply does not compute a difference in a phenotype between different strains of a species. In particular, Luo does not compute the difference between the alleles Q associated with line P_1 and the alleles q associated with line P_2 . Rather, lines P_1 and P_2 are crossed in Luo and the F_2 family is considered. See, for instance, page 237, second column, lines 5-8 of Luo which state “[i]n the F_2 family discussed previously, a sample of n individuals is scored for their quantitative phenotype, denoted by $Y = \{y_1, y_2, \dots, y_n\}$, and their marker genotype.” This data is then used to identify QTL in the genome of the F_2 generation using the methods discussed in Luo.

Luo does not disclose the claimed genotypic data structure. Claim 1 recites a genotypic data structure that comprises a variation of at least one component of the locus between different strains of a species. Page 16, line 5, through page 18, line 12, of the specification provide an example of a genotypic data structure. In the example, the claimed variation is counts of the polymorphic differences between strains for a locus L that contains M genetic variations, such as SNPs. An individual variation matrix S^x is established for each variation in every position x within a locus L . In each such matrix, S^x , the i^{th} row and the j^{th} column are associated with the allele value $l^x(i)$ for strain i and the allele value $l^x(j)$ for strain j at locus position x according to the following rule:

$$\begin{aligned} S^x(i, j) &= 1/2 \text{ if } l^x(i) = \emptyset \text{ or } l^x(j) = \emptyset \\ &= 0 \text{ if } l^x(i) = l^x(j) \\ &= 1 \text{ if } l^x(i) \neq l^x(j) \end{aligned}$$

where \emptyset indicates that the allelic value for strain i at locus position x is not known at the present time. Therefore, if the alleles for two strains i and j are identical at position x , the entry in the individual variation matrix for x is:

$$S^x(i, j) = S^x(j, i) = 0$$

and if the two alleles are different, a “1” is entered. In cases where allelic information is known the corresponding entry is set equal to one half. Thus, each individual variation matrix S contains elements that take on one of three values: 0, $\frac{1}{2}$, or 1. To illustrate, a variation matrix S that tracks an individual locus position x for five strains (M1 through M5) of a species can have the form:

S	M1	M2	M3	M4	M5
M1	0	0.5	0.5	1	0
M2	0.5	0	0.5	0	1
M3	0.5	0.5	0	1	1
M4	1	0	1	0	0.5
M5	0	1	1	0.5	0

In one embodiment of the present invention, in order to assemble the overall genotypic matrix for this locus, each individual variation matrix S within the locus L selected in processing step 204 is summed. See, for example, Applicants' specification, page 18, lines 1-12.

Claim 1 recites that the genotypic data structure comprises a variation of at least one component of the locus between different strains of the species. Thus, following the example described above, the genotypic data structure of claim 1 includes the values of at least one variation matrix S .

Luo does not have the claimed genotypic data structure. While the marker linkage map of Luo may indeed be considered a genotypic data structure, it does not include variation of at least one component (location) of a locus between different strains of the species as recited in claim 1 as amended.

Claims 3-10, 12, 13 and 18 ultimately depend from claim 1 and is therefore patentable over Luo for at least the same reasons that claim 1 is patentable over Luo.

For all of the above-identified reasons, Applicants respectfully request that the rejection of claims 1, 3-10, 12, 13, and 18 be withdrawn.

THE 35 U.S.C. § 103 REJECTION SHOULD BE WITHDRAWN

The PTO has rejected claims 1-13, 16, 18, 19, 23-28, 41, 43, 44, 48-57, 59-61, and 71 under 35 U.S.C. § 103(a) as allegedly being anticipated by Luo taken with United States Patent Number 6,132,724 to Blum (hereinafter “Blum”). With respect to claims 2, 27, and 51, the rejection is moot because the claims have been cancelled. With respect to claims 1, 3-13, 16, 18, 19, 23-26, 28, 41, 43, 44, 48-50, 52-57, 59-61, and 71, Applicants traverse the rejection.

To reject claims in an application under 35 U.S.C. § 103, the PTO bears the initial burden of establishing a *prima facie* case of obviousness. *In re Bell*, 26 USPQ2d 1529, 1530 (Fed. Cir. 1993). In order to establish *prima facie* obviousness, the prior art, either alone or in combination, must teach or suggest each and every limitation of the rejected claims. *In re Vaeck*, 20 USPQ2d 1438 (Fed. Cir. 1991); *In re Royka and Martin* 180 USPQ 580 (C.C.P.A. 1974); and *In re Wilson* 165 USPQ 494 (C.C.P.A. 1970).

Claims 1, 26, 52, and 71 each recite a phenotypic data structure that comprises a difference in a phenotype between different strains of a species. Further, claims 1, 26, 52, and 71 each recite a genotypic data structure that comprises a variation of at least one component of the locus between different strains of a species. As discussed in response to the 35 U.S.C. § 102 rejections above, Luo does not disclose such data structures. Blum also does not teach or suggest the claimed data structures. Therefore, claims 1, 26, 52, and 71 are patentable over the combination of Luo and Blum. Each of the remaining rejected claims depend from one of claims 1, 26, or 52 and are thus patentable over the combination of Luo and Blum for at least the same reasons that claims 1, 26, and 52 are patentable over Blum.

Claims 11, 16, 19, and 44 are patentable over the combination of Luo and Blum for the following additional reasons. The PTO indicates that column 7, lines 35-61, of Blum teaches phenotypic data structures and/or genotypic data structures in which each element in the structures represents a **difference** between a first and second cluster of strains of a species as respectively recited in claims 11 and 16. This is not the case. The cited section of Blum states “[t]he MCMI-II assessed schizoid/avoidant cluster compared to other Axis II diagnostic clusters (antisocial, narcissistic, paranoid) significantly correlated with alcohol abuse scales.” This cannot be equated to Applicants’ claims 11 and 16 for two reasons. First, claims 11 and 16 recite “clusters of **strains**” of a species. Blum does not disclose the comparison of strains of a species. Second, claims 11 and 16 are directed to a **difference**

between a first and second cluster of strains of a species. Blum is not directed to data structures that track **differences** in species, much less differences in clusters of strains. Claims 19 and 44 are directed to single nucleotide polymorphism, a genetic feature that is not referred to in column 7, lines 35-61, of Blum.

CONCLUSION

Applicants respectfully request entry of the foregoing amendments and remarks into the file of the above-identified application. Applicants believe that each ground for rejection has been successfully overcome or obviated, and that all the pending claims are in condition for allowance. Withdrawal of the Examiner's rejections and allowance of the application are respectfully requested.

Date: December 24, 2003

Respectfully submitted,
Brett J. George Reg. No. 42,813
24,615
Francis E. Morris (Reg. No.)
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York NY 10036-2720
(212) 790-9090

Enclosure



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APRIL 10, 2002

PTAS

ROCHE BIOSCIENCE
ROHAN PERIES
3401 HILLVIEW AVE
PATENT LAW DEPARTMENT M/S A2-250
PALO ALTO, CA 94304

700012041A

700012041A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 04/09/2002

REEL/FRAME: 012571/0790

NUMBER OF PAGES: 5

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

GROUPE, ANDREW

DOC DATE: 04/04/2002

ASSIGNOR:

PELTZ, GARY ALLEN

DOC DATE: 03/18/2002

ASSIGNOR:

USUKA, JONATHAN ANDREW

DOC DATE: 03/18/2002

ASSIGNEE:

SYNTEX (U.S.A.) LLC
3401 HILLVIEW AVENUE
PALO ALTO, CALIFORNIA 94304

SERIAL NUMBER: 10015167

FILING DATE: 12/11/2001

PATENT NUMBER:

ISSUE DATE:

SELDY PYNE, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

04/09/2002
700012041Form PTO-1885
1-0-02RECORDATION FORM COVER SHEET
PATENTS ONLY

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name and address of conveying party(ies):

1. Andrew Grupe
2. Gary Allen Peltz
3. Jonathan Andrew Usuka

2. Name and address of receiving party(ies):

SYNTEX (U.S.A.) LLC
3401 HILLVIEW AVENUE
PALO ALTO, CALIFORNIA 94304

3. Nature of conveyance: ASSIGNMENT

Execution Date of Assignment:

(1) 04-Apr-2002; (2) 18-Mar-2002; (3) 18-Mar-2002

4. Application number(s) or patent number(s):

A. Patent Application No.(s)

U.S. Serial No. 10/015,167, filed December 11, 2001

Attorney Docket No. R0108B-CIP

B. Patent No.(s)

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: ROHAN PERIES

Address: ROCHE BIOSCIENCE
PATENT LAW DEPARTMENT M/S A2-250
3401 HILLVIEW AVE
PALO ALTO, CALIFORNIA 94304

6. Total number of applications and patents involved:

ONE

7. Total fee (37 CFR 3.41)..... \$ 40.00

[] Enclosed

[X] Authorized to be charged to deposit account

8. Deposit Account Number: 18-1700

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Mona Anand Reg. 34,537

Name of Person Signing

Mona Anand

Signature

4/9/02

Date

Total number of pages including cover sheet, attachments and document: [5]

ASSIGNMENT

RBS No. R0108B-CIP

WHEREAS, We, Andrew Grupe, Gary Allen Peltz and Jonathan Andrew Usuka ("Assignors") having the respective addresses indicated below, have invented certain subject matter entitled "**System and Method for Predicting Chromosomal Regions That Control Phenotypic Traits**" (the "Invention"), described in patent application U.S. Serial No.10/015,167, filed December 11, 2001, for Letters Patent of the United States of America (the "Application");

AND WHEREAS, Syntex (U.S.A.) LLC, a company of Delaware, having an address at 3401 Hillview Avenue, Palo Alto, California 94304 ("Syntex"), desires to perfect its right to the Invention and in the Letters Patent(s) to be obtained therefor from the United States of America and all countries foreign thereto;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignors acknowledge Syntex's interest in the Invention and hereby assign to Syntex for the United States of America and all countries foreign thereto all our rights, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in the Invention, as described and claimed in patent application U.S. Serial No.10/015,167, or in any subsequent patent application(s) filed under 35 U.S.C. §111(a), claiming benefit of said Application under 35 U.S.C. §119(e), or 35 U.S.C. §120, or in any continuation, continuation-in-part, continued prosecution application, divisional, substitute, reissue, reexamination or extension thereof and any legal equivalent thereof in a country foreign to the United States of America; the Invention, application and Letters Patent(s) to be owned by Syntex, its successors, assigns and legal representatives, to the full end of the term for which such Letters Patent(s) may be granted.

Assignors hereby covenant that they have the full right to convey the entire interest assigned herein and have not executed and will not execute any agreement in conflict herewith.

Assignors further covenant to execute and deliver upon request and without undue delay, to Syntex, its successors, assigns and legal representatives, all lawful documents necessary or desirable to effect this assignment and perfect the title to the Invention, Application and Letters Patent(s) and all foreign patents and applications claiming priority thereto.


Assignors further covenant to cooperate and participate in any administrative or legal proceeding and execute all lawful documents necessary or desirable for Syntex, its successors, assigns and legal representatives to obtain, maintain and enforce patent protection in the Invention in all countries, provided that Syntex reimburses Assignors for any expenses incurred therewith by Assignors.

ASSIGNMENT

RBS No. R0108B-CIP

This assignment is effective as of the earlier of the date of execution of this document or the filing date accorded by the United States Patent and Trademark Office to patent application U.S. Serial No.10/015,167, as indicated in the Filing Receipt for said Application.

I have read and understand this Assignment document for the Application, and agree hereto, as indicated by my signature as set forth below.

Signature  Date 4/04/02
Andrew Grupe
554 Jeter Street, Redwood City, California 94062

Signature  Date 3/18/02
Gary Allen Peltz
110 Danbury Lane, Redwood City, California 94061

Signature  Date 3/18/02
Jonathan Andrew Usuka
220 Chestnut Avenue, Palo Alto, California 94306

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

State of California

County of Santa Clara

} ss.

On 18-March-2002, before me, Christina G. Myers, Notary Public

Date

Name and Title of Officer (e.g., "Jane Doe, Notary Public")


personally appeared Gary Allen Peltz and Jonathan Andrew Usuka

Name(s) of Signer(s)


personally known to me
 proved to me on the basis of satisfactory evidence

to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.


Signature of Notary Public

Place Notary Seal Above



OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document: assignment inventors to Syntex (USA) LLC for U.S. patent application 10/015,167, filed December 11, 2001

Document Date: _____ Number of Pages: _____

Signer(s) Other Than Named Above: Andrew Grupe

Capacity(ies) Claimed by Signer

Signer's Name: _____

Individual
 Corporate Officer — Title(s): _____
 Partner — Limited General
 Attorney in Fact
 Trustee
 Guardian or Conservator
 Other: _____

RIGHT THUMBPRINT
OF SIGNER

Top of thumb here

Signer Is Representing: self

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

State of California

County of ALAMEDA

} ss.

On APRIL 4, 2002, before me, YVETH GRACE LOCSIN
Date _____

Name and Title of Officer (e.g., "Jane Doe, Notary Public")

personally appeared ANDREW GRUPE

Name(s) of Signer(s)

personally known to me
 proved to me on the basis of satisfactory evidence

to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies); and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.



Signature of Notary Public

Place Notary Seal Above

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document: _____

Document Date: _____ Number of Pages: _____

Signer(s) Other Than Named Above: _____

Capacity(ies) Claimed by Signer

Signer's Name: _____

Individual
 Corporate Officer — Title(s): _____
 Partner — Limited General
 Attorney in Fact
 Trustee
 Guardian or Conservator
 Other: _____

RIGHT THUMPRINT
OF SIGNER

Top of thumb here

Signer Is Representing: _____



Express Mail No. EV 313 842 590 US

**RECORDATION FORM COVER SHEET
PATENTS ONLY**

Attorney Docket Number
9080-008-999

Mail Stop Assignment Recordation Services
Director of the United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Please record the attached original documents or copy thereof.

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s) 10/015,167

B. Patent No.(s)

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:	6. Number of applications and patents involved:	<u>1</u>
PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, New York, 10036-2711	7. Total fee (37 CFR 3.41): \$ 40.00 Please charge to the deposit account listed in Section 8.	
8. Deposit account number: 16-1150		

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. *D-119* *0-20-4282*

Francis E. Morris
Name of Person Signing

24,615

Reg. No.

Signature

December 24, 2003

Date

Total number of pages including cover sheet:

3

Mail documents to be recorded with required cover sheet information to:

Mail Stop Assignment Recordation Services

Director of the United States Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450


Delaware

PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "SYNTEX (U.S.A.) LLC", CHANGING ITS NAME FROM "SYNTEX (U.S.A.) LLC" TO "ROCHE PALO ALTO LLC", FILED IN THIS OFFICE ON THE TWENTY-THIRD DAY OF DECEMBER, A.D. 2002, AT 4 O'CLOCK P.M.

3205906 8100
030585329



Harriet Smith Windsor

Harriet Smith Windsor, Secretary of State

AUTHENTICATION: 2627285

DATE: 09-11-03

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 04:00 PM 12/23/2002
020794267 - 3205906

CERTIFICATE OF AMENDMENT
OF
SYNTEX (U.S.A.) LLC

1. The name of the limited liability company is, upon the effective time of this amendment, Roche Palo Alto LLC.


2. The Certificate of Formation of the limited liability company is hereby amended as follows:

The paragraph labeled "FIRST" is changed to read, The name of the limited liability company formed hereby is Roche Palo Alto LLC.

The heading is changed to read, CERTIFICATE OF FORMATION OF ROCHE PALO ALTO LLC.

3. This Certificate of Amendment shall be effective on 12:01 am, January 1, 2003.

IN WITNESS WHEREOF, the undersigned has executed this Certificate of Amendment of Syntax (U.S.A.) LLC this 20th day of December, 2002.



Nancy M. Cohen
Vice President, Secretary

06084 - 3/12/2001 CT System Online

CODEMNN 119635.v11
12/19/02 at 11:14 AM

TOTAL P.02